IMPORTANCE A relapse into nicotine addiction during abstinence often occurs after the reactivation of nicotine reward memories, either by acute exposure to nicotine (a smoking episode) or by smoking-associated conditioned stimuli (CS). Preclinical studies suggest that drug reward memories can undergo memory reconsolidation after being reactivated, during which they can be weakened or erased by pharmacological or behavioral manipulations. However, translational clinical studies using CS-induced memory retrieval-reconsolidation procedures to decrease drug craving reported inconsistent results.
animal models, 5, 6 key triggers of craving and relapse during abstinence are acute reexposure to nicotine (the unconditioned stimulus, [UCS], a smoking episode for people or noncontingent nicotine priming injections in laboratory animals) or nicotine-associated conditioned stimuli (CS), presumably because of reactivation of nicotine-associated memories. 7, 8 Nicotine-associated memories may undergo reconsolidation, a time-dependent process in which consolidated memories become unstable for several hours after their reactivation. [9] [10] [11] Preclinical studies suggest that reconsolidation requires activation of the noradrenergic system.
12-14
Human studies have shown that the administration of the β-adrenoceptor blocker propranolol before or after memory reactivation decreases conditioned fear among healthy individuals, fear of spiders among arachnophobic individuals, 15 or psychophysiological responses induced by traumatic imagery scripts among individuals with posttraumatic stress disorder. 16 ,17 Propranolol administration after memory retrieval also impairs reconsolidation of drug-related memories in rat models, 14,18-23 and among people addicted to heroin. 24 However, other studies failed to demonstrate an effect of propranolol on drug craving among people who use drugs.
25-27
One potential reason for the limited "translational" utility of propranolol's effect on drug craving is that previous human studies exposed participants to drug-associated CS, not (UCS), to induce memory retrieval and reconsolidation. Under these experimental conditions, propranolol or other neuropharmacological manipulations interfere with the reconsolidation of memories selectively associated with the reactivated CS. [28] [29] [30] [31] In the context of nicotine addiction, smoking is associated with multiple CS that vary across individuals. 32 It is not feasible to reactivate all of a smoker's nicotine-associated CS in a clinical or laboratory setting. Based on these considerations and findings that interference with reconsolidation after retrieval by UCS (aversive shock) prevented subsequent fear expression induced by multiple CS, 28, 29, 33 we recently developed a UCS-induced memory retrieval-reconsolidation interference procedure and demonstrated its efficacy in decreasing relapse to cocaine seeking and craving in rat models. 31 In the present study, we introduced a memory retrieval-reconsolidation interference procedure that is based on our rat study 31 in which we reactivated nicotine reward memories in both rat models and among people who smoke by acute exposure to nicotine (the UCS) and then interfered with memory reconsolidation using propranolol. In the rat study, we assessed the efficacy of our procedure using animal models of drug relapse 6 ,34 based on the CPP 35 and intravenous drug self-administration 36 procedures. In the human study, we assessed the efficacy of our new procedure using a laboratory method in which drug craving during abstinence was assessed after exposing the participants to drug-associated cues 27,37-39 or drug priming. 40 
Methods

Rat Study
The timelines of the experiments are provided in eFigure 1 and 2intheSupplement.
We housed male 156 Sprague-Dawley rats (260-280 g; Vitalriver Company) in individual cages in a temperature-(23±2°C) and humidity-(50 ±5%) controlled animal facility with unlimited access to food and water. We performed the experimental procedures in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the procedures were approved by the Biomedical Ethics Committee for animal use and protection of Peking University. The procedures for training and testing for nicotine CPP are similar to those of our previous studies. [41] [42] [43] The training and extinction procedures are also similar to those of previous studies by our group and others. [44] [45] [46] [47] [48] We injected the rats noncontingently with the previously self-administered drug (nicotine 0.15 mg/kg, subcutaneous, the UCS) in their home cage. We based the nicotine UCS retrieval dose on previous studies using the reinstatement procedure, 46, 48, 49 and these studies also guided our choice for the nicotine priming dose during the reinstatement tests described later. We based the propranolol dose (10 mg/kg, intraperitoneal) and the timing of the injections on previous studies of reconsolidation of drug memories in rats.
18-20
The UCS and CS memory retrieval manipulations were based on those used in our previous studies. 31, 45 This information is described in the eMethods in the Supplement.
Human Study
The timeline of the study is provided in eFigure 3 in the Supplement and a description of the experimental phases is provided in the eMethods in the Supplement.
Participants
We recruited 96 healthy young men through posters and online advertisements. Because of the multisession aspect of the study, we enrolled only men to avoid the influence of the menstrual cycle phase on the response to nicotine stimulant effects and craving induced by nicotine-associated cues. 50,51 The inclusion criteria were that participants had to be men between the ages of 18 and 45 years who had been smoking 10 or more cigarettes per day continuously for at least 12 months prior to the screening, were willing to refrain from smoking for at least a night, had an afternoon end-exhaled carbon monoxide concentration less than or equal to 10 ppm (Bedfont Mini2 Smokerlyzer; Bedfont Scientific Ltd), and were in general good health as determined by a physician. Participants were excluded if they had used addictive drugs other than nicotine based on self-reporting or had a positive urine test result during either the recruitment screening or testing, had a current or past history of DSM-IV Axis I disorders, were currently using antidepressants or had depression diagnosed, had clinically evident cognitive impairment, or had self-reported treatment with any prescription drugs during the previous 2 weeks or any over-the-counter drugs during the 3 days prior to the experimental sessions. Eligible candidates were scheduled for a screening interview during which they read the study protocol and signed the informed consent form. The study was approved by the institutional review boards of Peking University Health Center, and all participants were paid for their participation. During the baseline session, we collected demographic data (age, sex, and education) and self-reports of the number of cigarettes per day and the Fagerström Test of Nicotine Dependence Score, and we also assessed depression and anxiety using standard measures.
Intervention
We chose the dose of propranolol (40 mg, oral; Zhongnuo Pharma) based on previous studies on memory reconsolidation among people with spider phobias 15 and people addicted to heroin. 24 We administered propranolol 1 hour before the memory retrieval manipulation rather than 1 hour after retrieval as in the rat study, because plasma concentrations of propranolol peak approximately 1 hour after oral administration, 52 and we were concerned that postretrieval oral administration might delay effective brain concentrations of propranolol until after the typical 1 to 2 hour "reconsolidation window."
53,54
The delayed 6-hour propranolol administration condition (a standard control condition in rodent and human memory studies) is based on previous human studies on propranolol's effect on reconsolidation of fear memories.
Overall Design In a double-blind experimental design, we recruited 96 participants and randomly assigned them to 1 of 3 groups, but it in the statistical analyses, we excluded 27 participants because they did not complete the experiment. The 3 groups of participants included: placebo plus 1 hour plus UCS, propranolol plus 1 hour plus UCS, and UCS plus 6 hours plus propranolol, all in a 1:1:1 ratio. During the randomization period, an independent (blind) team member, who was only involved in the rat experiments, generated a table of randomization codes using Microsoft Excel software. Other team members who were responsible for the random allocation of the patients, drug administration, and the subsequent memory tests during the study were blind to the drug condition. We gave the participants the placebo and propranolol in identical capsules. We used methods from previous studies with some modifications. 55,56 There were 6 sessions: screening and baseline tests of preference (liking) and craving for "pre-existing" nicotine CS (day 1), conditioning for 3 different CS to be paired or not paired (CS-) with smoking (day 2-4), postconditioning test of preference and craving for the CS (day 5), UCS memory reactivation and propranolol or placebo administration (day 6), a posttreatment test (day 7), and a priming test (day 8) (eFigure 3 in the Supplement). We asked the participants to abstain from smoking for at least 8 hours (overnight) before the daily experimental sessions, and verified short-term abstinence by examining their carbon monoxide level (less than 8 ppm) before the sessions. 57 We instructed the participants to continue their usual daily smoking habits and not to attempt to quit smoking while in the study.
Assessment of Nicotine Craving and Preference (Liking)
Based on previous studies, 45,55 we measured subjective ratings of "liking" and craving. For ratings of "liking," we marked the scale at the left and right ends with -5 ("dislike") and 5 ("like very much") and with 0 ("neutral") at the midpoint. For ratings of craving, we marked the scale at the left and right ends with 0 ("extremely low") and 10 ("extremely high"). The participants had to rate their current craving level to smoke or their preference for the different CS after exposure to the different experimental manipulations (see earlier).
Statistical Analysis
We reported the results as mean (standard error of the mean) and analyzed the data by analyses of variance (ANOVAs) with the appropriate between-and within-subject factors for each experiment (eTable in the Supplement). We excluded 22 participants because they did not meet the smoking citeria and 5 participants because they decided to quit the study during the conditioning phase and included 69 participants (24 for placebo plus 1 hour plus UCS, 23 for propranolol plus 1 hour plus UCS, and 22 for UCS plus 6 hours plus propranolol) for data analysis. No statistical methods were used to predetermine sample sizes, but they are similar to those reported in our previous studies of rats and humans. 14,21, 45 We performed post hoc analyses of significant effects in ANOVAs using the Tukey test. We also performed post hoc analyses and report the Cohen d estimate and its 95% CIs using R software (3.3.1 version). Values of P less than or equal to .05, 2-tailed, were considered statistically significant.
Results
Effect of Propranolol on Reconsolidation of Multiple Nicotine Reward Memories After UCS Retrieval in Rats
In the first experiement, we found that propranolol administration (10 mg/kg, intraperitoneal) within the reconsolidation time window after UCS exposure decreased nicotine preference in the CPP procedure and relapse to nicotine seeking in the drug self-administration procedure (eFigures 4 and 5 in the Supplement).
In the second experiement, we developed a modified training procedure in which we trained rats for both nicotine selfadministration (14 days) and then nicotine CPP (8 days), resulting in the formation of both Pavlovian and operant reward memories in the same rat (eFigures 1 and 2 in the Supplement). For the nicotine UCS retrieval procedure, the analysis showed a significant main effect of the propranolol dose (0, 10 mg/kg) on both the CPP test (mixed ANOVA, F 1,15 = 6.59, P = .02, Figure 1A ) and the nicotine-seeking test (F 1,15 = 13.65, P = .002, Figure 1B ). By contrast, for the operant CS retrieval procedure, the analysis showed a significant main effect of the propranolol dose on the nicotine-seeking test (mixed ANOVA, F 1,13 = 13.94, P = .003, Figure 2 ) but not the CPP test (F 1,13 = 0.02, P = .88, Figure 2 ).
These results indicate that propranolol injections after UCS retrieval disrupted both nicotine CPP and selfadministration memories, leading to the inhibition of nicotine CPP and operant nicotine seeking. By contrast, propranolol injections administered after operant CS memory retrieval selectively disrupted nicotine self-administration memories, leading to the inhibition of operant nicotine seeking but not nicotine CPP.
We also examined whether propranolol injections administered after nicotine UCS retrieval affect reward memories for sucrose. We found that propranolol prevented nicotine CPP 1 day later but had no effect on sucrose seeking in the extinction test (eFigure 3 in the Supplement).
Effect of UCS-Induced Memory Interference Procedure on Multiple Nicotine-Associated Memories and Nicotine Craving Among Smokers
In the third experiment, we tested whether the findings from the rat studies would generalize in relation to people who Systemic injections of propranolol administered immediately after exposure to operant-CS retrieval decreased cue-induced operant nicotine seeking (B) but not nicotine conditioned place preference (CPP) (A). Vehicle, 7 rats; propranolol, 8 rats. Data are mean (stand error of the mean). a Different from the vehicle group, mixed analysis of variance, P < .05.
signed the 96 smokers (69 of whom completed the experiment) to 3 experimental groups: placebo plus 1 hour plus UCS retrieval, propranolol plus 1 hour plus UCS retrieval, or UCS retrieval plus 6-hours plus propranolol (eFigure 3 in the Supplement). The participants' demographic data are shown in the Table. Nicotine Preference The analysis of preference (liking) for the newly learned CS on days 5 and 7 showed a significant group × test interaction (mixed ANOVA, F 2,198 = 7.75, P = .001) and cue type × test interaction (F 2,198 = 4.69, P = .01) ( Figure 3A ). The analysis of preference (liking) for the newly learned CS during the priming test showed significant main effects of group (2-way ANOVA, F 2,198 =10 . 19 ,P < .001) and cue type (F 2,198 = 6.75, P = .001) ( Figure 3A ). The analysis of preference (liking) for the preexisting real-life CS indicated a significant group × test interaction (mixed ANOVA, F 2,66 =3.74,P = .03) ( Figure 3B ) in the posttreatment test and a significant main effect of group (1-way ANOVA, F 2,66 = 11.14, P < .001) in the nicotine priming test ( Figure 3B ). These results demonstrate that propranolol administration within the time window of memory reconsolidation after UCS retrieval decreased the participants' preference (liking) to both newly learned and preexisting nicotine-associated CS.
Nicotine Craving
We also examined the effect of propranolol plus UCS retrieval on nicotine craving induced by newly learned and preexisting CS and nicotine priming. For newly learned CS, there were no significant group differences (mixed-measures ANOVA, P > .1) in the posttreatment test ( Figure 4A ). By contrast, for preexisting CSs, there was a significant group × test interaction (mixed ANOVA, F 2,66 = 5.82, P = .005) in the posttreatment test and a significant main effect of group (1-way ANOVA, F 2,66 = 7.91, P = .001) in the priming test ( Figure 4B ). These results showed that nicotine craving in our procedure was induced by preexisting but not newly learned nicotine- A and B, Propranolol administration 1 hour prior to but not 6 hours after UCS retrieval decreased subsequent preference for newly learned and preexisting nicotine-associated CS, as well as nicotine priming-induced preference for these CS. Post hoc analyses of propranolol 1 hour vs placebo 1 hour. associated cues, but more importantly, that propranolol plus UCS retrieval decreased the nicotine craving induced by preexisting CS and nicotine priming.
Discussion
In this rat-to-human translational study, we introduced a UCSinduced memory retrieval-reconsolidation interference procedure in which we reactivated nicotine reward memories by acute exposure to nicotine (the UCS) and then pharmacologically interfered with the putative process of memory reconsolidation. In rat relapse models, systemic injections of the β-adrenoceptor blocker propranolol immediately after UCSinduced, but not CS-induced, memory retrieval inhibited subsequent nicotine CPP and relapse to operant nicotine seeking after short or prolonged abstinence. Among people who smoke, propranolol administration decreased subsequent nicotine preference induced by both newly learned and preexisting (ie, real-life) nicotine CS, and nicotine craving induced by the preexisting nicotine CS and nicotine priming. In both rats and humans, the pharmacological manipulations had no effect on any of these behavioral measures when administered 6 hours after UCS retrieval (outside the temporal window within which reconsolidation is thought to occur 58 ), supporting a memory reconsolidation account of the present results.
UCS Memory Retrieval vs CS Memory Retrieval
Since 2005, 59 ,60 many studies using rats and mice showed that consolidated drug-associated memories undergo reconsolidation when reactivated by drug-associated CS, and that neuropharmacological or behavioral interference with reconsolidation can inhibit subsequent drug CPP and relapse into operant drug seeking. 14,21,61,62 However, with few exceptions, 45,63 the "translation" of these preclinical studies to people addicted to drugs has not been successful. [25] [26] [27] This situation, and the realization that a major limitation of CS-induced retrieval and reconsolidation procedures is their specificity to the reactivated CS, 28,29,33 inspired us to develop an alternative procedure in which the drug-reward memories are reactivated by exposure to the drug itself (the UCS). In a recent study, 31 we introduced a UCS memory retrievalextinction procedure and showed that, unlike the more established CS-induced procedure, 45,64 the UCS-induced procedure can prevent relapse into cocaine seeking induced by multiple cocaine-associated CS under a wide range of experimental conditions. However, from a clinical perspective, the UCS memory retrieval-extinction procedure can be difficult to implement, because it requires multiple sessions of UCS retrieval plus extinction training. By contrast, the UCS memory retrieval-reconsolidation procedure described here was effective among rats and humans after a single UCS session. Additionally, in the human translational study, the procedure's effects generalized to multiple nicotine CS during the early abstinence period. Furthermore, in rats trained for both nicotine CPP and operant nicotine self-administration, reconsolidation interference after nicotine UCS retrieval inhibited both nicotine CPP and operant nicotine seeking. By contrast, reconsolidation interference after CPP-CS or operant CS memory retrieval selectively inhibited subsequent nicotine CPP, but not operant nicotine seeking and vice versa, respectively. Together, the findings across species suggest that the UCSinduced memory retrieval-reconsolidation interference procedures are more promising for relapse prevention than the CS-induced procedures.
Methodological and Translational Considerations and Limitations
Before we reach the goal of clinical implementation, several issues should be considered. First, the results of our human A, Exposure to the newly learned nicotine CS (CS1 and CS2) did not induce craving for cigarettes, and propranolol had no effect on this measure (P > .10). B, Propranolol administration 1 hour prior to but not 6 hours after UCS retrieval decreased subsequent craving induced by exposure to the preexisting nicotine-associated CS and nicotine priming. Post hoc analyses of propranolol 1 hour vs placebo 1 hour. study were limited to the measurement of craving and preference during an early abstinence period within a laboratory setting. Craving often precedes and predicts drug relapse, but is neither necessary nor sufficient for it to occur. 65,66 Additionally, the response to drug-associated CS in rat models 67 and among people 68 is often context-specific. Even after prolonged extinction of the response to drug CS within a nondrug context, the same CS can provoke relapse in the drug environment. Thus, we still need to test whether the UCSinduced memory retrieval-reconsolidation interference procedure will decrease craving and relapse in the smokers' home environments. In the absence of data from a larger clinical study with additional outcome measures, we cannot draw strong conclusions about the clinical utility of the procedure. Another issue to consider from a translational perspective is that the timing of propranolol administration differed between our rat and human studies: we administered propranolol after UCS retrieval in rats but prior to UCS retrieval in the human study because of the pharmacokinetics of oral administration in humans. This was a procedural necessity, but it complicates our data interpretation. Specifically, it cannot be ruled out that propranolol's effect on nicotine preference and craving among people was because of interference with memory retrieval rather than memory reconsolidation. Another issue arising in our human study is that under our experimental conditions, nicotine craving were only observed after exposure to preexisting CS, not newly learned CS. This observation agrees with results from a previous study using a similar procedure 69 and is likely because of insufficient pairings between the new CS and cigarette smoking. Finally, the generalizability of our results is limited by our having used only males of each species. We recognize that this approach is no longer tenable 70 because of sex differences in nicotine's effects and smoking cessation, 50,51,71 andweplanto address it in the future.
Conclusions
We introduced a UCS-induced memory retrieval-reconsolidation interference procedure and demonstrated its efficacy in simultaneously preventing nicotine CPP and operant nicotine seeking during prolonged abstinence periods in a rat model. Our results among people who smoke suggest that a UCS-induced procedure may be a promising method for decreasing nicotine craving. Additionally, to the degree that results from rat models generalize to drug addiction among people, 72 the potential value of the procedure should be tested for the prevention of relapse to smoking. Committee for animal use and protection of Peking University. We used 156 rats, of which 4 rats were excluded because of loss of the dental cement and catheter patency during the SA training, and 10 rats were excluded because they exhibited strong unconditio ned side preference (> 540 s) during the nicotine preconditioning phase.
Training for nicotine conditioned place preferences (CPP) and init ia l C PP test
The CPP procedure is based on our previous studies [1] [2] [3] . The apparatus for CPP conditioning and testing consisted of 20 polyvinyl chloride boxes, identical except for their floors. The boxes had two large side chambers (27.9 cm long × 21.0 cm wide × 20.9 cm high) with different floors (bar or grid, respectively), separated by a smaller chamber (12.1 cm long × 21.0 cm wide × 20.9 cm high with a smooth polyvinyl chloride floor). In each box, the three chambers were separated by manual guillotine doors.
To determine baseline preference, we init ia l ly placed rats in the middle chamber with the doors removed and allowed them free access to all compartments for 15 min (baseline test). A computer measured the time spent in each of the chambers during the 15-min session through interruptio ns of infrared beams. Most rats spent approximately one-third of the time in each chamber (data not shown). The conditioning was performed using an unbiased, balanced protocol.
We performed CPP training over 8 consecutive days with alternating injectio ns of nicotine (0.5 mg/kg, s.c.) and saline (1 ml/kg, s.c.). After each injection, we confined the rats to the corresponding conditioning chambers for 45 min before being returned to their home cages. The day after the last conditioning session, we tested the rats for the expression of nicotine-ind uce d CPP (Test 1) under conditio ns identica l to those described for the baseline test. We calculated the CPP score as the time spent in the nicotine-paired chamber minus the time spent in the saline-paired chamber.
Extinctio n of nicotine CPP Extinction training was identical to the initial CPP training, except that no injections were given. The day after the 4 consecutive days of extinctio n training, which included 2 sessions in the nicotine-pa ire d side and 2 sessions in the saline-paired side, we tested again the rats for CPP expression (Test 2).
N icotine-priming-ind uced reinstatement of CPP
The nicotine priming-induced reinstatement of CPP procedure is based on our previous studies [1] [2] [3] . Five min before the CPP reinstatement test, we injected the rats with nicotine (0.25 mg/kg, s.c.). The experimental procedure during the reinstatement test was the same as those for the baseline preference test and CPP tests 1-2. The reinstate me nt tests were performed by an investigator blinded to condition.
Intravenous nicotine self-administration (SA)
We anesthetized the rats (weighing 300-320 g when surgery began) with sodium pentobarbital (60 mg/kg, i.p.) and inserted the catheters into the right jugular vein with the tip termina ting at the opening of the right atrium as previous ly described 4 . We allowed the rats to recover for 5-7 days after surgery. The operant chambers (AniLab Software and Instruments) were equipped with two nosepoke operandi (AniLab Software and Instruments) located 5 cm above the chamber floor. Nosepokes in the active operandum led to nicotine infusions that were accompanied by a 5-s tone-light cue.
Nosepokes in the inactive operandum were also recorded but had no programmed consequences. The modified cannula on the rat's skull was connected to a liquid swivel with polyethylene-50 tubing protected by a metal spring and leading to a 10-ml syringe infusion pump. We trained the rats to self-administer nicotine bitartrate (0.03 mg/kg/infus io n) during two 1-h daily sessions separated by 5 min over 14 days. The sessions began at the onset of the dark cycle. We used a fixed-ratio 1 (FR1) reinforcement schedule, with a 40-s timeout period after each infusion. Each session began with the illum ina t io n of a houselight that remained on for the entire session. At the end of the training phase, the groups in the different experimental conditions were matched for their nicotine intake during training. These training conditions and nicotine unit dose are based on previous studies [5] [6] [7] [8] [9] .
Sucrose self-administration
The experimental conditions were identical to those described above for nicotine self-administration, with the exception that active nosepoke responses led to 0.1 ml of sucrose (10%) delivered into a liquid receptacle.
Extinctio n of nicotine-reinforced responding During extinctio n, the conditio ns were the same as during training, except that nicotine was no longer available; that is, nosepoke responses led to a 5-s tone-light cue under the FR1 40-s timeout reinforcement schedule. We gave the rats extinction training until responding on the active nosepoke operandum was less than 20% of mean responding during the last 3 days of nicotine self-administration for at least 2 consecutive days.
N icotine priming-ind uced reinstate me nt of operant responding
Once responding on the active nosepoke operandum was successfully extinguis he d
per the criterion described above, testing commenced. The extinction tests were performed by an investigator blinded to condition. The test conditions were the same as during training, with the exception that active nosepokes were not reinforced by nicotine.
Each session began with illumina tio n of the houselight, which remained on for the entire session. Nosepoke responding during the test sessions resulted in continge nt presentations of the tone-light cue that had previously been paired with nicotine infus io ns but not nicotine. During the nicotine priming reinstatement tests, we injected nicotine (0.3 mg/kg, s.c.) 5 min before the start of the sessions. The nicotine priming dose is based on previous studies 5, 6 .
Drugs and injections
We dissolved nicotine tartrate (Xinxiang Crude Medicinal N icotines Co.), and
propranolol HCl (#A9789, St. Louis, Sigma-A ld r ic h) in 0.9% physiological saline and intraperitoneally injected at a dose of 10 mg/kg; this dose is based on previous studies [8] [9] [10] .
Exp. 1:
Effect of systemic injections of propranolol on reconsolidation of nicotine CPP memories and SA memories in rats (eFigure 4A and 5A)
In the CPP experiment, we first assessed baseline preferences of rats (8 groups, n=8-10 per group) for the two chambers of the CPP apparatus (test 1, 15 min session).
Next, we trained the rats to associate one context with the effect of nicotine injections (0.5 mg/kg, s.c., 4 pairings) and to associate another context with the effect of saline injections (1 ml/kg, 4 pairings); we then assessed the expression of CPP (test 2, 15 min session). Twenty-four h later, we divided the rats in the first run into 4 groups (n=8-10 per group). We exposed two groups of rats to the nicotine-paired side of CPP apparatus for 5 min [C PP-conditioned stimulus (CPP-CS) retrieval] and injected two other groups of rats with a low dose of nicotine (0.15 mg/kg, s.c.; unconditio ned stimulus (UCS) retrieval). Immediately after CPP-CS or UCS retrieval, we injected the rats with propranolol (10 mg/kg, i.p.) or its vehicle (saline). CPP expression was assessed 1 day (test 3, 15 min session) and 14 days (test 4, 15 min session) later. Next, we gave rats 4 days of extinctio n training and tested for extinctio n of CPP (test 5, 15 min session).
Twenty-four h later, we determined reinstatement of nicotine CPP after an acute injection of nicotine priming (0.25 mg/kg, s.c., test 6, 15 min session).
In the 2 nd run of the CPP experiment, we used 4 other groups of rats to determine whether the effect of propranolol is temporally specific and dependent on UCS retrieval.
We performed the baseline preference (test 1), CPP training, and CPP expression (test 2)
as described above. Twenty-four h later, we exposed two groups of rats (n=8 per group)
to nicotine UCS retrieval in homecage (0.15 mg/kg, s.c.) and injected propranolol (10 mg/kg, i.p.) or vehicle 9 h later. We also injected two other groups of rats (n=8 per group) with saline in homecage and immediately after that injected them propranolol or vehicle. We then determined CPP expression 1 day later (test 3).
In the self-administration experiment, we used two groups of rats (n=9-12 per group)
that we trained to self-administe r intraveno us nicotine (0.03 mg/kg/inf us io n, infus io n volume 50 µl) during two 1-h daily sessions over 14 days under an FR1 40-s timeout reinforcement schedule; nicotine infusions were paired with a 5-s compound tone-light cue. Twenty-four h later, we exposed the rats to a low dose of nicotine (0.15 mg/kg, s.c.;
UCS retrieval) in the homecage and immediately after that injected them with propranolol (10 mg/kg, i.p.) or saline. We then determined cue-induced nicotine seeking under extinctio n conditions 1 day (extinctio n test 1) and 30 days (extinctio n test 2) later.
Next, we exposed the rats to extinction training for 5 daily two 1-h sessions. Twenty-fo ur h after last extinction session, we tested the rats for reinstatement of nicotine seeking induced by a priming injection of nicotine (0.3 mg/kg, s.c., test 3, 1-h session). The nicotine priming dose is based on previous studies 5, 6, 11 .
Exp. 2:
Effect of systemic injectio ns of propranolol on reconsolidat io n of mult ip le nicotine reward memories in rats (eFigure 1 & 2)
We first trained all rats in the nicotine SA procedure (14 d), as described in Exp. 1.
Next, we determined baseline preference (CPP test 1), and then trained the rats in the CPP procedure (8 d), as described in Exp. 1, and subsequently assessed the expression of learned CPP (CPP test 2). Twenty-fo ur h later, we divided the rats into 4 groups. We injected two groups of rats (n=7-9 per group) with a low dose of nicotine (0.15 mg/kg, s.c.; UCS retrieval) and exposed two other groups of rats to a 15 min-extinc tio n session in the SA chamber (operant-CS retrieval); immediately after UCS retrieval or operant-CS retrieval, we injected the rats with propranolol (10 mg/kg, i.p.) or vehicle (saline). We then determined the CPP expression 1 d (CPP test 3) and 15 days (CPP test 4) after the retrieval manipulations, and cue-induced nicotine seeking under extinctio n conditions 2 days (extinction test 1) and 16 days (extinction test 2) after these manipulations.
We then used four groups of rats (n=8-10 per group) to examine whether systemic nicotine UCS retrieval plus propranolol affect sucrose seeking (eFigure 6A). We trained of the rats to nosepoke for oral sucrose (a potent non-nicotine reward in rodents) solution (10%) over 10 days and nicotine CPP over 8 days. Twenty-four h later, we exposed the rats to a low dose of nicotine (0.15mg/kg, s.c.; nicotine UCS retrieval), and immediately injected them with propranolol (10 mg/kg, i.p.) or vehicle (saline). We then determined subsequent nicotine CPP expression (CPP test 3) and cue-induced sucrose seeking under extinct io n conditio ns (extinctio n test).
Human s tudy
The experimental procedure included six sessions in the human study.
baseline measures (day 1):
The participants completed questionnaires assessing their basic demographics, nicotine/alcohol/illicit nicotine use, and medical and psychiatric history, and were then shown a series of choices of GIF images to be used later as CS, consisting of shapes (square, circle and triangle) in different colors (black, white, red, green, and blue). We measured subjective ratings of "liking" and "craving" visual analogue scales (range 5-5 for "liking" rating, and range 0-10 for "craving" rating) after e xpos ure to the future CS a nd a fter e xpo s ure to established smoking-associated cues, includ in g a lighter, ashtray, and a new pack of cigarettes (termed herein 'preexisting CS'). The effectiveness of these preexisting CS was established in a preliminary study (data not shown).
Conditioning training (days 2-4):
This phase included two days of CS+ trials and one day of a CS-trial in a counterbalanced order. During the CS+ trials, we instructed the participants to pay attention to the CS1 or CS2 (one of two CS on each day) on the computer screen, and to smoke two cigarettes of their preferred brand during a 10-min period. During the CS-trial, we instructed the participants to pay attention to the CSimage for 10 min without smoking. We counterbalanced the images used as CS+ and CS− across participants, and we randomized the sequence of exposure to the CS1, CS2, unpaired CS-within each subject. We exposed each subject to one pairing trial with each CS.
Conditioning test (day 5):
During this test, we measured subjective ratings of 'liking' and 'craving' on the VAS after exposure to CS1 or CS2 (termed herein newly learned CS) or the unpaired CS-. We presented the CS1, CS2, and CS-in a random order for each subject. We then exposed the participants to the pre-existing nicotine CS 1 h later.
UCS memory retrieval (day 6):
During the UCS memory reactivatio n session, the participants smoked two puffs of a cigarette (1/6 of a cigarette), and either 1 h before or 6 h after UCS retrieval we gave them oral propranolol (40 mg) or placebo.
5-6. Post-retrieval and priming tests (days 7-8):
We measured subjective ratings of 'liking' and 'craving' on the VAS after exposure to CS1 or CS2 (the newly learned nicotine CS) or the unpaired CS-and exposure to the pre-existing nicotine CS (day 7), which was identical to conditioning test. We also measured subjective ratings of 'liking'
and 'craving' after the participants smoked two puffs from their preferred cigarette brand (a nicotine priming manipulation) (day 8).
Specific Operant-Related Nicotine Reward Memories After Operant-C S Memory Retrieva l.
We trained rats in the nicotine self-administration and CPP procedures. Twenty-fo ur h later, we exposed the rats to a short 15-min extinct io n session in the self-administration training chamber (operant-CS retrieval), and immediately after that injected them with propranolol or vehicle. We then tested them for CPP expression (CPP tests 3 and 4) and operant nicotine seeking (extinction tests 1s and 2). We trained rats in the nicotine self-administration and CPP procedures. Twenty-fo ur h later, we exposed the rats to the nicotine UCS retrieval (0.15 mg/kg, in homecage) and immediately after this injected them with propranolol (10 mg/kg, i.p.) or vehicle. We then tested the rats for CPP expression (CPP tests 3 and 4) and operant nicotine seeking (extinctio n tests 1 and 2). . The experiment included six phases: (1) baseline test of preference (liking) and craving for' pre-existing' nicotine CS (e.g., ashtray, cigarette package) and for three different CS to be paired (CS1, CS2, 'newly learned' nicotine CS) or not paired (CS-) with smoking (day 1); (2) conditioning training during which CS1 and CS2 were paired with smoking and CS-was not (days 2-4; see extended Methods); (3) post-training test of preference and craving for the new learned CS (day 5); (4) UCS memory retrieval (smoking two puffs of smoking a cigarette) that preceded (1 h) by propranolol (40 mg, p.o) or placebo administration, or UCS memory retrieval that was followed 6 h later by propranolol administration (day 6); (5) post-UCS retrieval tests of preference and craving after exposure to the newly learned and pre-existing CS (day 7); and (6) nicotine priming (smoking two puffs of a cigarette, day 7). mg/kg, UCS retrieval) or saline in the homecage; we then injected the rats with propranolol (10 mg/kg) immed ia te ly after the retrieva l manipula t io ns or 9 h later. We determined nicotine CPP expression 1 day (test 3) and 14 days (test 4) later. Next, we gave the rats extinction trainings and verified that nicotine CPP was extinguished (test 5).
Twenty-four h later, we tested the rats for reinstatement of CPP after priming injections of nicotine (0.25 mg/kg) (Test 6 
